European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011)
Human adenovirus (HAdV) infections are increasingly recognized as important pathogens in immunocompromised hosts, especially in patients with severely suppressed T‐cell function. The 4th European Conference of Infections in Leukemia (ECIL‐4) has developed evidence‐based guidelines for diagnosis and...
Gespeichert in:
| Veröffentlicht in: | Transplant infectious disease 2012-12, Vol.14 (6), p.555-563 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 563 |
|---|---|
| container_issue | 6 |
| container_start_page | 555 |
| container_title | Transplant infectious disease |
| container_volume | 14 |
| creator | Matthes-Martin, S. Feuchtinger, T. Shaw, P.J. Engelhard, D. Hirsch, H.H. Cordonnier, C. Ljungman, P. |
| description | Human adenovirus (HAdV) infections are increasingly recognized as important pathogens in immunocompromised hosts, especially in patients with severely suppressed T‐cell function. The 4th European Conference of Infections in Leukemia (ECIL‐4) has developed evidence‐based guidelines for diagnosis and management of HAdV infections. The risk for HAdV‐associated disease is increased in children, and risk factors for HAdV disease are T‐cell depletion, unrelated and cord blood hematopoietic stem cell transplantation, graft‐versus‐host disease grades III–IV, and lymphopenia. The recommended technique for monitoring of high‐risk patients is quantitative polymerase chain reaction. Cidofovir is the most used antiviral therapy, although no controlled study has been performed. HAdV‐specific T‐cell therapy is in development. |
| doi_str_mv | 10.1111/tid.12022 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_533423</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1285087284</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5282-8475d9018d0d90beba9e98d07c5c92f055d85803de308410b709b952cbfee0ac3</originalsourceid><addsrcrecordid>eNqNkc1u1DAUhSMEoqWw4AWQJTbtIq1_4sRmh4ZpOzCAQEVdWk58U7mT2MFOWvoMvDSen84CCQlv7rX1naN7fbLsNcGnJJ2z0ZpTQjGlT7JDwqTMGS7p000vckordpC9iPEWY1LJQj7PDigjRYlLdpj9nk_BD6Adupmsgc46iKj1ARmrb5yPNiLtDBoD6LEHNyLfIm3A-Tsbpoisa6EZrXepQx1MK-it3ijiCD1qoOuSVrs4dNqNek2-Q3Hqex0e1lbz2WKZF-iYYkJOXmbPWt1FeLWrR9mP8_nV7DJffr1YzN4v84ZTQXNRVNxITITBqdRQawkyXaqGN5K2mHMjuMDMAMOiILiusKwlp03dAmDdsKMs3_rGeximWg3BrudRXlu1e1qlDhRnrKAs8cdbfgj-5wRxVL2N69W0Az9FRajgWFRUFP-DUlyUFPOEvv0LvfVTcGnxRNFSSFJIkqiTLdUEH2OAdj8twWodvkrhq034iX2zc5zqHsyefEw7AWdb4N528PBvJ3W1-PBoufsqm_L8tVfosFJlxSqurr9cKHr97TP5fvlJfWR_AGKSx10</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1226891491</pqid></control><display><type>article</type><title>European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011)</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Matthes-Martin, S. ; Feuchtinger, T. ; Shaw, P.J. ; Engelhard, D. ; Hirsch, H.H. ; Cordonnier, C. ; Ljungman, P.</creator><creatorcontrib>Matthes-Martin, S. ; Feuchtinger, T. ; Shaw, P.J. ; Engelhard, D. ; Hirsch, H.H. ; Cordonnier, C. ; Ljungman, P. ; Fourth European Conference on Infections in Leukemia ; The fourth European Conference on Infections in Leukemia</creatorcontrib><description>Human adenovirus (HAdV) infections are increasingly recognized as important pathogens in immunocompromised hosts, especially in patients with severely suppressed T‐cell function. The 4th European Conference of Infections in Leukemia (ECIL‐4) has developed evidence‐based guidelines for diagnosis and management of HAdV infections. The risk for HAdV‐associated disease is increased in children, and risk factors for HAdV disease are T‐cell depletion, unrelated and cord blood hematopoietic stem cell transplantation, graft‐versus‐host disease grades III–IV, and lymphopenia. The recommended technique for monitoring of high‐risk patients is quantitative polymerase chain reaction. Cidofovir is the most used antiviral therapy, although no controlled study has been performed. HAdV‐specific T‐cell therapy is in development.</description><identifier>ISSN: 1398-2273</identifier><identifier>EISSN: 1399-3062</identifier><identifier>DOI: 10.1111/tid.12022</identifier><identifier>PMID: 23146063</identifier><language>eng</language><publisher>Denmark: Blackwell Publishing Ltd</publisher><subject>Adenovirus ; Adenovirus Infections, Human - diagnosis ; Adenovirus Infections, Human - etiology ; Adenovirus Infections, Human - therapy ; Adenoviruses ; Children ; Cidofovir ; Conferences ; Cord blood ; Development ; Europe ; Graft-versus-host reaction ; guidelines ; Human adenovirus ; Humans ; Immunocompromised hosts ; Infection ; Infections ; Leukemia ; Leukemia - complications ; Lymphocytes T ; Lymphopenia ; Pathogens ; Polymerase chain reaction ; Practice Guidelines as Topic ; Risk factors ; Risk groups ; stem cell ; stem cell transplantation ; Stem Cell Transplantation - adverse effects ; Stem cells ; Transplants & implants</subject><ispartof>Transplant infectious disease, 2012-12, Vol.14 (6), p.555-563</ispartof><rights>2012 John Wiley & Sons A/S</rights><rights>2012 John Wiley & Sons A/S.</rights><rights>2012 Wiley Periodicals, Inc</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5282-8475d9018d0d90beba9e98d07c5c92f055d85803de308410b709b952cbfee0ac3</citedby><cites>FETCH-LOGICAL-c5282-8475d9018d0d90beba9e98d07c5c92f055d85803de308410b709b952cbfee0ac3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Ftid.12022$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Ftid.12022$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23146063$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:125828817$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Matthes-Martin, S.</creatorcontrib><creatorcontrib>Feuchtinger, T.</creatorcontrib><creatorcontrib>Shaw, P.J.</creatorcontrib><creatorcontrib>Engelhard, D.</creatorcontrib><creatorcontrib>Hirsch, H.H.</creatorcontrib><creatorcontrib>Cordonnier, C.</creatorcontrib><creatorcontrib>Ljungman, P.</creatorcontrib><creatorcontrib>Fourth European Conference on Infections in Leukemia</creatorcontrib><creatorcontrib>The fourth European Conference on Infections in Leukemia</creatorcontrib><title>European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011)</title><title>Transplant infectious disease</title><addtitle>Transpl Infect Dis</addtitle><description>Human adenovirus (HAdV) infections are increasingly recognized as important pathogens in immunocompromised hosts, especially in patients with severely suppressed T‐cell function. The 4th European Conference of Infections in Leukemia (ECIL‐4) has developed evidence‐based guidelines for diagnosis and management of HAdV infections. The risk for HAdV‐associated disease is increased in children, and risk factors for HAdV disease are T‐cell depletion, unrelated and cord blood hematopoietic stem cell transplantation, graft‐versus‐host disease grades III–IV, and lymphopenia. The recommended technique for monitoring of high‐risk patients is quantitative polymerase chain reaction. Cidofovir is the most used antiviral therapy, although no controlled study has been performed. HAdV‐specific T‐cell therapy is in development.</description><subject>Adenovirus</subject><subject>Adenovirus Infections, Human - diagnosis</subject><subject>Adenovirus Infections, Human - etiology</subject><subject>Adenovirus Infections, Human - therapy</subject><subject>Adenoviruses</subject><subject>Children</subject><subject>Cidofovir</subject><subject>Conferences</subject><subject>Cord blood</subject><subject>Development</subject><subject>Europe</subject><subject>Graft-versus-host reaction</subject><subject>guidelines</subject><subject>Human adenovirus</subject><subject>Humans</subject><subject>Immunocompromised hosts</subject><subject>Infection</subject><subject>Infections</subject><subject>Leukemia</subject><subject>Leukemia - complications</subject><subject>Lymphocytes T</subject><subject>Lymphopenia</subject><subject>Pathogens</subject><subject>Polymerase chain reaction</subject><subject>Practice Guidelines as Topic</subject><subject>Risk factors</subject><subject>Risk groups</subject><subject>stem cell</subject><subject>stem cell transplantation</subject><subject>Stem Cell Transplantation - adverse effects</subject><subject>Stem cells</subject><subject>Transplants & implants</subject><issn>1398-2273</issn><issn>1399-3062</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc1u1DAUhSMEoqWw4AWQJTbtIq1_4sRmh4ZpOzCAQEVdWk58U7mT2MFOWvoMvDSen84CCQlv7rX1naN7fbLsNcGnJJ2z0ZpTQjGlT7JDwqTMGS7p000vckordpC9iPEWY1LJQj7PDigjRYlLdpj9nk_BD6Adupmsgc46iKj1ARmrb5yPNiLtDBoD6LEHNyLfIm3A-Tsbpoisa6EZrXepQx1MK-it3ijiCD1qoOuSVrs4dNqNek2-Q3Hqex0e1lbz2WKZF-iYYkJOXmbPWt1FeLWrR9mP8_nV7DJffr1YzN4v84ZTQXNRVNxITITBqdRQawkyXaqGN5K2mHMjuMDMAMOiILiusKwlp03dAmDdsKMs3_rGeximWg3BrudRXlu1e1qlDhRnrKAs8cdbfgj-5wRxVL2N69W0Az9FRajgWFRUFP-DUlyUFPOEvv0LvfVTcGnxRNFSSFJIkqiTLdUEH2OAdj8twWodvkrhq034iX2zc5zqHsyefEw7AWdb4N528PBvJ3W1-PBoufsqm_L8tVfosFJlxSqurr9cKHr97TP5fvlJfWR_AGKSx10</recordid><startdate>201212</startdate><enddate>201212</enddate><creator>Matthes-Martin, S.</creator><creator>Feuchtinger, T.</creator><creator>Shaw, P.J.</creator><creator>Engelhard, D.</creator><creator>Hirsch, H.H.</creator><creator>Cordonnier, C.</creator><creator>Ljungman, P.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope></search><sort><creationdate>201212</creationdate><title>European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011)</title><author>Matthes-Martin, S. ; Feuchtinger, T. ; Shaw, P.J. ; Engelhard, D. ; Hirsch, H.H. ; Cordonnier, C. ; Ljungman, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5282-8475d9018d0d90beba9e98d07c5c92f055d85803de308410b709b952cbfee0ac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adenovirus</topic><topic>Adenovirus Infections, Human - diagnosis</topic><topic>Adenovirus Infections, Human - etiology</topic><topic>Adenovirus Infections, Human - therapy</topic><topic>Adenoviruses</topic><topic>Children</topic><topic>Cidofovir</topic><topic>Conferences</topic><topic>Cord blood</topic><topic>Development</topic><topic>Europe</topic><topic>Graft-versus-host reaction</topic><topic>guidelines</topic><topic>Human adenovirus</topic><topic>Humans</topic><topic>Immunocompromised hosts</topic><topic>Infection</topic><topic>Infections</topic><topic>Leukemia</topic><topic>Leukemia - complications</topic><topic>Lymphocytes T</topic><topic>Lymphopenia</topic><topic>Pathogens</topic><topic>Polymerase chain reaction</topic><topic>Practice Guidelines as Topic</topic><topic>Risk factors</topic><topic>Risk groups</topic><topic>stem cell</topic><topic>stem cell transplantation</topic><topic>Stem Cell Transplantation - adverse effects</topic><topic>Stem cells</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matthes-Martin, S.</creatorcontrib><creatorcontrib>Feuchtinger, T.</creatorcontrib><creatorcontrib>Shaw, P.J.</creatorcontrib><creatorcontrib>Engelhard, D.</creatorcontrib><creatorcontrib>Hirsch, H.H.</creatorcontrib><creatorcontrib>Cordonnier, C.</creatorcontrib><creatorcontrib>Ljungman, P.</creatorcontrib><creatorcontrib>Fourth European Conference on Infections in Leukemia</creatorcontrib><creatorcontrib>The fourth European Conference on Infections in Leukemia</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>Transplant infectious disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matthes-Martin, S.</au><au>Feuchtinger, T.</au><au>Shaw, P.J.</au><au>Engelhard, D.</au><au>Hirsch, H.H.</au><au>Cordonnier, C.</au><au>Ljungman, P.</au><aucorp>Fourth European Conference on Infections in Leukemia</aucorp><aucorp>The fourth European Conference on Infections in Leukemia</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011)</atitle><jtitle>Transplant infectious disease</jtitle><addtitle>Transpl Infect Dis</addtitle><date>2012-12</date><risdate>2012</risdate><volume>14</volume><issue>6</issue><spage>555</spage><epage>563</epage><pages>555-563</pages><issn>1398-2273</issn><eissn>1399-3062</eissn><abstract>Human adenovirus (HAdV) infections are increasingly recognized as important pathogens in immunocompromised hosts, especially in patients with severely suppressed T‐cell function. The 4th European Conference of Infections in Leukemia (ECIL‐4) has developed evidence‐based guidelines for diagnosis and management of HAdV infections. The risk for HAdV‐associated disease is increased in children, and risk factors for HAdV disease are T‐cell depletion, unrelated and cord blood hematopoietic stem cell transplantation, graft‐versus‐host disease grades III–IV, and lymphopenia. The recommended technique for monitoring of high‐risk patients is quantitative polymerase chain reaction. Cidofovir is the most used antiviral therapy, although no controlled study has been performed. HAdV‐specific T‐cell therapy is in development.</abstract><cop>Denmark</cop><pub>Blackwell Publishing Ltd</pub><pmid>23146063</pmid><doi>10.1111/tid.12022</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1398-2273 |
| ispartof | Transplant infectious disease, 2012-12, Vol.14 (6), p.555-563 |
| issn | 1398-2273 1399-3062 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_533423 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adenovirus Adenovirus Infections, Human - diagnosis Adenovirus Infections, Human - etiology Adenovirus Infections, Human - therapy Adenoviruses Children Cidofovir Conferences Cord blood Development Europe Graft-versus-host reaction guidelines Human adenovirus Humans Immunocompromised hosts Infection Infections Leukemia Leukemia - complications Lymphocytes T Lymphopenia Pathogens Polymerase chain reaction Practice Guidelines as Topic Risk factors Risk groups stem cell stem cell transplantation Stem Cell Transplantation - adverse effects Stem cells Transplants & implants |
| title | European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T22%3A44%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=European%20guidelines%20for%20diagnosis%20and%20treatment%20of%20adenovirus%20infection%20in%20leukemia%20and%20stem%20cell%20transplantation:%20summary%20of%20ECIL-4%20(2011)&rft.jtitle=Transplant%20infectious%20disease&rft.au=Matthes-Martin,%20S.&rft.aucorp=Fourth%20European%20Conference%20on%20Infections%20in%20Leukemia&rft.date=2012-12&rft.volume=14&rft.issue=6&rft.spage=555&rft.epage=563&rft.pages=555-563&rft.issn=1398-2273&rft.eissn=1399-3062&rft_id=info:doi/10.1111/tid.12022&rft_dat=%3Cproquest_swepu%3E1285087284%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1226891491&rft_id=info:pmid/23146063&rfr_iscdi=true |